Format

Send to

Choose Destination
Indian J Ophthalmol. 2019 Feb;67(2):233-238. doi: 10.4103/ijo.IJO_675_18.

Intermediate-term outcome of Aurolab aqueous drainage implant.

Author information

1
Department of Glaucoma, Aravind Eye Hospital, Coimbatore, Tamil Nadu, India.

Abstract

Purpose:

To report the intermediate-term safety and efficacy of Aurolab aqueous drainage implant (AADI) in patients with glaucoma.

Methods:

Retrospective review of patients who underwent AADI between January 2013 and December 2016. Patients aged >16 years and with a minimum follow-up of 6 months were included. Success was defined as complete when the intraocular pressure was ≥6 and ≤21 mmHg without antiglaucoma medication and as qualified if those requiring additional antiglaucoma medications were included.

Results:

The study included 55 patients (55 eyes) with a mean age ± standard deviation (SD) of 47.3 ± 18.1 years with a mean follow-up of 16.7 ± 11.4 months. Mean intraocular pressure reduced from 30.8 ± 11.1 mmHg to 13.1 ± 4.7, 14.1 ± 4.8, 15.7 ± 2.5 (P < 0.001) mmHg at 6 months, 1 year, and 2 years, respectively. The mean number of antiglaucoma medications reduced from 3.4 ± 1 to 0.8 ± 1.2, 0.7 ± 1.1, 0.8 ± 1 (P < 0.001) at 6 months, 1 year, and 2 years, respectively. The cumulative probability of complete and qualified success was 62% and 100% at 6 months, 54% and 92% at 1 year, and 43% and 88% at 2 years, respectively. Four patients failed during the follow-up period. Postoperative complication occurred in 28 eyes (51%), of which 17 eyes (31%) required intervention.

Conclusion:

AADI is a safe and effective treatment for the control of intraocular pressure in patients with glaucoma.

KEYWORDS:

Adult glaucoma; Aurolab aqueous drainage implant; glaucoma drainage device

PMID:
30672476
DOI:
10.4103/ijo.IJO_675_18
Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center